Fierce Pharma May 3, 2024
Ayla Ellison, Kevin Dunleavy

This week on “The Top Line,” we’re diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year.

Fierce Pharma Senior Writer Kevin Dunleavy sits down with Cody Powers, a consultant who advises companies on business development and franchise growth strategy, to discuss the reasons behind the numerous high-value deals in 2023, which companies are...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
How AI is streamlining cell and gene therapy manufacturing
Kroger partners with Express Scripts to expand pharmacy services
Denali’s Data in Rare Enzyme Deficiency Keep It on Pace to Seek Speedy FDA Approval
Vertex challenger Sionna prices $191M IPO
Some of the Biggest Healthcare Stories from 2024 Involved Pharmacy. What’s Next in 2025?

Share This Article